Lupus Lupus Lupus talk two: Dawn Caster, the moderator, calls her own number and is going to speak on New Options and Brighter Future. #NKFClinicals
Patient call. Had to miss a chunk of her talk. Sorry #ClinicalNephrologistProblems #NKFClinicals
We target proteinuria because reducing proteinuria is associated with good outcomes. Turns out, people whose kidneys heal have better outcomes. #NKFClinicals
KDIGO Standard of care for Lupus Nephritis #NKFClinicals
Simplified (?) version of the above with new b-cell agents: belimumab and rituximab. #NKFClinicals
AURORA 1: voclosporin with MMF and reduced dose steroids vs placebo, MMF, reduced dose steroids.
52-week renal response: UPCR ≤0.5, eGFR ≥60, no rescue medications.
It worked. Adverse events were similar.
Now FDA approved. #NKFClinicals
Next up B-cell therapies.
Many targets. Many drugs. #NKFClinicals
BLISS-LN 2 year trial, one of the longest. 448 patients. Belimumab monthly IV infusion vs placebo. Primary outcome PERR: #NKFClinicals
It worked.
Looked at those renal events
Adverse events were balanced #NKFClinicals
The pipeline #NKFClinicals
NOBILITy is phase 2 trial of obinutuzumab B-cell depleting drug. Works at 2 years Improved renal end-points and bio markers. Looking forward to phase three data. #NKFClinicals
Share this Scrolly Tale with your friends.
A Scrolly Tale is a new way to read Twitter threads with a more visually immersive experience.
Discover more beautiful Scrolly Tales like this.